Loading…
Tvardi Therapeutics, Inc. is projected to decline to $3.23 by 2027, a -2% move from its current price of $3.30. TVRD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.17 | $3.30 | $3.43 | -0.04% |
| May 30 | $3.11 | $3.30 | $3.49 | -0.08% |
| May 31 | $3.07 | $3.30 | $3.53 | -0.12% |
| Jun 1 | $3.04 | $3.29 | $3.57 | -0.16% |
| Jun 2 | $3.01 | $3.29 | $3.60 | -0.21% |
| Jun 3 | $2.98 | $3.29 | $3.63 | -0.25% |
| Jun 4 | $2.96 | $3.29 | $3.66 | -0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.96 | $3.29 | $3.66 | -0.29% |
| Week 2 | $2.82 | $3.28 | $3.82 | -0.57% |
| Week 3 | $2.72 | $3.27 | $3.94 | -0.86% |
| Week 4 | $2.64 | $3.26 | $4.04 | -1.14% |
| Week 5 | $2.56 | $3.25 | $4.13 | -1.43% |
| Week 6 | $2.50 | $3.24 | $4.21 | -1.71% |
| Week 7 | $2.44 | $3.23 | $4.29 | -1.99% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need in the United States.
Its lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Tvardi Therapeutics, Inc. trades under the symbol TVRD. The current price is $3.30 with a market cap of $30.96M, and the company ranks 4740 by market capitalization.
The year-by-year forecast paints a longer-term price path, starting with a 2026 average near $3.30 and progressing to higher levels later in the decade and into the 2040s/2050s. The forecast shows a 2030 average of $4.34 and an eventual 2050 average of $16.17, with a max predicted price of $6.95 in 2030 and $35.24 in 2050, suggesting meaningful long-run upside despite near-term volatility.
The near-term and longer-term outlook combine a bearish-to-neutral technical stance in the short run with a bullish longer-term trajectory supported by the forecasted average and max price levels.
A major floor 30.1% below — a decisive break under it would weaken the trend.
The nearest floor, 8.8% below — buyers have tended to step in here.
The nearest ceiling, 27.6% above — a clean break opens room to run.
A major ceiling 46.4% above — clearing it would confirm fresh momentum.
Key TVRD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TVRD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.55 | Sell | $3.51 | Sell |
| MA 10 | $3.74 | Sell | $3.63 | Sell |
| MA 20 | $3.70 | Sell | $3.63 | Sell |
| MA 50 | $3.41 | Sell | $3.64 | Sell |
| MA 100 | $3.72 | Sell | $4.82 | Sell |
| MA 200 | $10.36 | Sell | $8.53 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.12 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -93.52 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | -21.05 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.55 | Buy |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 27.01 | Buy |
| Momentum (10) | -0.68 | Sell |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 3.35 | Sell |
| ADX (14) | 16.57 | Neutral |
| ATR (14) | 0.13 | Info |
The 30-day technical picture shows bearish sentiment.
RSI14 is 40; SMA50 is $3.41; SMA200 is $10.36. Support sits at $3.01 and resistance at $4.21.
The 30-day price range runs from a low of $2.53 to a high of $4.31, highlighting the recent trading band as the stock tests key levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.85 | $3.30 | $4.51 | 0% | Neutral | |
| $2.45 | $3.23 | $4.59 | -2% | Neutral | |
| $2.21 | $3.05 | $4.55 | -8% | Neutral | |
| $2.48 | $3.55 | $5.51 | +8% | Neutral | |
| $2.94 | $4.34 | $6.95 | +32% | Bullish | |
| $3.31 | $5.03 | $8.28 | +52% | Bullish | |
| $3.18 | $4.98 | $8.41 | +51% | Bullish | |
| $2.87 | $4.62 | $7.97 | +40% | Bullish | |
| $2.91 | $4.80 | $8.46 | +45% | Bullish | |
| $3.05 | $5.16 | $9.28 | +56% | Bullish | |
| $3.50 | $6.66 | $12.95 | +102% | Bullish | |
| $7.27 | $16.17 | $35.24 | +390% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.85 | $3.30 | $3.92 | +0.00% |
| June 2026 | $2.80 | $3.32 | $4.06 | +0.54% |
| July 2026 | $2.65 | $3.18 | $3.96 | -4.19% |
| August 2026 | $2.65 | $3.22 | $4.08 | +1.36% |
| September 2026 | $2.72 | $3.33 | $4.27 | +3.47% |
| October 2026 | $2.65 | $3.27 | $4.23 | -1.94% |
| November 2026 | $2.61 | $3.24 | $4.24 | -0.81% |
| December 2026 | $2.74 | $3.42 | $4.51 | +5.52% |
Click any year to see its month-by-month TVRD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Tvardi Therapeutics, Inc.'s 2026 outlook centres on $3.30, within a $2.85 to $4.51 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, TVRD could reach as high as $4.59, with a base case around $3.23 and support toward $2.45 — roughly -2% from $3.30. Price action looks broadly range-bound.
Expect TVRD to range from $2.21 to $4.55 through 2028. The $3.05 average target implies a -8% move from current prices. That is -6% versus the projected 2027 average. A consolidation phase looks the most probable path here.
The TVRD price prediction for 2029 points to an average of $3.55 (low $2.48, high $5.51) — a potential gain of +8% on today's $3.30. Price action looks broadly range-bound.
In 2030, TVRD is projected to trade between $2.94 and $6.95, averaging $4.34 — a potential gain of +32% from today's $3.30. That is up +22% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Tvardi Therapeutics, Inc.'s 2031 outlook centres on $5.03, within a $3.31 to $8.28 range. That is up +16% on the projected 2030 average. That marks a +52% change versus current levels. Momentum favours further upside here.
By 2032, TVRD could reach as high as $8.41, with a base case around $4.98 and support toward $3.18 — roughly +51% from $3.30. Buyers look set to stay in control over this stretch.
Expect TVRD to range from $2.87 to $7.97 through 2033. The $4.62 average target implies a +40% move from current prices. That is -7% versus the projected 2032 average. Momentum favours further upside here.
The TVRD price prediction for 2034 points to an average of $4.80 (low $2.91, high $8.46) — a potential gain of +45% on today's $3.30. Buyers look set to stay in control over this stretch.
In 2035, TVRD is projected to trade between $3.05 and $9.28, averaging $5.16 — a potential gain of +56% from today's $3.30. That is up +8% on the projected 2034 average. Momentum favours further upside here.
Tvardi Therapeutics, Inc.'s 2040 outlook centres on $6.66, within a $3.50 to $12.95 range. That is up +29% on the projected 2035 average. That marks a +102% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, TVRD could reach as high as $35.24, with a base case around $16.17 and support toward $7.27 — roughly +390% from $3.30. Momentum favours further upside here.
Investing $1,000 in TVRD today (≈ 303.030303 TVRD) could be worth
$4,898.91
+$3,898.91 (+390%) by 2050 · US Dollar
Based on the average projected TVRD price of $16.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TVRDwould be worth at today's price.
$1,000 invested in TVRD on May 27, 2025 (≈ 29.949087 TVRD) would be worth
$98.83
-$901.17 (-90.1%) today · 0.10× · US Dollar
Based on a TVRD entry price of $33.39 vs. today's $3.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.85 | $857.14 | -14.3% |
| 1 month ago | $3.04 | $1,085.53 | +8.6% |
| 3 months ago | $4.05 | $814.81 | -18.5% |
| 6 months ago | $4.12 | $800.97 | -19.9% |
| 1 year ago | $33.39 | $98.83 | -90.1% |
| All time (5.0y) ago | $477.72 | $6.91 | -99.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TVRD forecast.
Our base-case forecast reaches $6.60 around 2040.
Implied market cap at $6.60: $61.92M
The year-by-year forecast depicts a mixed start, with 2026 min $2.85, avg $3.30, max $4.51 and neutral sentiment, followed by continued neutral readings through 2028.
From 2030 onward, a clear bullish trajectory emerges, with 2030 avg $4.34 and ROI 31.6%, followed by stronger bullish readings in the early 2030s (2031 avg $5.03; ROI 52.5%; 2032 avg $4.98; ROI 51%; 2033 avg $4.62; ROI 39.9%; 2034 avg $4.80; ROI 45.4%; 2035 avg $5.16; ROI 56.5%).
The forecast then points to substantial upside by 2040 (avg $6.66; min $3.50; max $12.95; ROI 101.7%) and even higher by 2050 (avg $16.17; min $7.27; max $35.24; ROI 389.9%). The sentiment remains BULLISH in these later years, reflecting a prolonged growth scenario with meaningful upside potential but also inherent volatility and uncertainty.
Tap a question to reveal the answer.
Avg price is forecast at $4.34, with a min of $2.94 and a max of $6.95, and ROI of 31.6%. The sentiment for 2030 is BULLISH.
Forecasts indicate a long-term bullish trajectory with an average price of $4.34 in 2030 and $16.17 in 2050, and a max of $6.95 in 2030 and $35.24 in 2050, yielding ROIs of 31.6% and 389.9% respectively. Near term, the 2026–2028 period shows neutral sentiment and modest downside risk, alongside substantial volatility (annualized volatility 80%). These figures are estimates, not guarantees, and not financial advice.
Yes. The forecast max reaches $12.95 by 2040 and $35.24 by 2050, while 2030 max is $6.95. This implies that a $10 level could be reached along the forecast horizon, particularly by 2040 onward.
Current price is $3.30 and market cap is $30.96M.
The 30-day range is $2.53 to $4.31. RSI14 is 40; SMA50 is $3.41; SMA200 is $10.36. Support is at $3.01 and resistance at $4.21; sentiment is BEARISH.
Tvardi Therapeutics, Inc. Community Discussion
0Share your Tvardi Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.